|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SYTL1 |
Gene summary for SYTL1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SYTL1 | Gene ID | 84958 |
| Gene name | synaptotagmin like 1 | |
| Gene Alias | JFC1 | |
| Cytomap | 1p36.11 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | Q8IYJ3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 84958 | SYTL1 | P61T-E | Human | Esophagus | ESCC | 1.44e-15 | 5.98e-01 | 0.099 |
| 84958 | SYTL1 | P62T-E | Human | Esophagus | ESCC | 6.78e-63 | 1.49e+00 | 0.1302 |
| 84958 | SYTL1 | P65T-E | Human | Esophagus | ESCC | 1.06e-46 | 1.14e+00 | 0.0978 |
| 84958 | SYTL1 | P74T-E | Human | Esophagus | ESCC | 2.82e-49 | 1.65e+00 | 0.1479 |
| 84958 | SYTL1 | P75T-E | Human | Esophagus | ESCC | 3.53e-52 | 1.36e+00 | 0.1125 |
| 84958 | SYTL1 | P76T-E | Human | Esophagus | ESCC | 3.03e-07 | 3.60e-01 | 0.1207 |
| 84958 | SYTL1 | P79T-E | Human | Esophagus | ESCC | 2.66e-11 | 4.77e-01 | 0.1154 |
| 84958 | SYTL1 | P80T-E | Human | Esophagus | ESCC | 1.99e-19 | 9.50e-01 | 0.155 |
| 84958 | SYTL1 | P82T-E | Human | Esophagus | ESCC | 1.99e-13 | 9.53e-01 | 0.1072 |
| 84958 | SYTL1 | P83T-E | Human | Esophagus | ESCC | 4.40e-30 | 1.26e+00 | 0.1738 |
| 84958 | SYTL1 | P84T-E | Human | Esophagus | ESCC | 1.61e-08 | 9.89e-01 | 0.0933 |
| 84958 | SYTL1 | P89T-E | Human | Esophagus | ESCC | 1.21e-03 | 5.74e-01 | 0.1752 |
| 84958 | SYTL1 | P91T-E | Human | Esophagus | ESCC | 2.67e-07 | 1.23e+00 | 0.1828 |
| 84958 | SYTL1 | P104T-E | Human | Esophagus | ESCC | 6.37e-06 | 7.43e-01 | 0.0931 |
| 84958 | SYTL1 | P107T-E | Human | Esophagus | ESCC | 2.06e-35 | 1.04e+00 | 0.171 |
| 84958 | SYTL1 | P127T-E | Human | Esophagus | ESCC | 8.02e-15 | 1.84e-01 | 0.0826 |
| 84958 | SYTL1 | P128T-E | Human | Esophagus | ESCC | 1.82e-33 | 1.53e+00 | 0.1241 |
| 84958 | SYTL1 | P130T-E | Human | Esophagus | ESCC | 1.28e-38 | 1.08e+00 | 0.1676 |
| 84958 | SYTL1 | C04 | Human | Oral cavity | OSCC | 4.06e-10 | 7.04e-01 | 0.2633 |
| 84958 | SYTL1 | C21 | Human | Oral cavity | OSCC | 3.59e-40 | 1.49e+00 | 0.2678 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00068874 | Oral cavity | EOLP | exocytosis | 60/2218 | 352/18723 | 2.32e-03 | 1.43e-02 | 60 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SYTL1 | SNV | Missense_Mutation | c.252C>G | p.Phe84Leu | p.F84L | Q8IYJ3 | protein_coding | deleterious(0) | probably_damaging(0.958) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| SYTL1 | insertion | Frame_Shift_Ins | novel | c.457_458insCCATAGCAGGAAAAATACA | p.Glu153AlafsTer10 | p.E153Afs*10 | Q8IYJ3 | protein_coding | TCGA-AN-A0XT-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | ||
| SYTL1 | SNV | Missense_Mutation | novel | c.1400G>A | p.Arg467His | p.R467H | Q8IYJ3 | protein_coding | tolerated(0.32) | benign(0.226) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| SYTL1 | SNV | Missense_Mutation | novel | c.388G>C | p.Glu130Gln | p.E130Q | Q8IYJ3 | protein_coding | tolerated(0.18) | benign(0.134) | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
| SYTL1 | SNV | Missense_Mutation | novel | c.722N>T | p.Ser241Leu | p.S241L | Q8IYJ3 | protein_coding | deleterious(0) | probably_damaging(0.922) | TCGA-VS-A952-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
| SYTL1 | SNV | Missense_Mutation | rs376143341 | c.949N>T | p.Arg317Cys | p.R317C | Q8IYJ3 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-3672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| SYTL1 | SNV | Missense_Mutation | rs148530866 | c.1348N>A | p.Val450Met | p.V450M | Q8IYJ3 | protein_coding | deleterious(0) | probably_damaging(0.96) | TCGA-AA-3821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SYTL1 | SNV | Missense_Mutation | c.1136A>C | p.Glu379Ala | p.E379A | Q8IYJ3 | protein_coding | tolerated(0.1) | benign(0.039) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| SYTL1 | SNV | Missense_Mutation | rs774540763 | c.1462N>T | p.Arg488Cys | p.R488C | Q8IYJ3 | protein_coding | tolerated(0.06) | benign(0.035) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SYTL1 | SNV | Missense_Mutation | c.958G>A | p.Ala320Thr | p.A320T | Q8IYJ3 | protein_coding | tolerated(0.35) | benign(0.026) | TCGA-CM-6168-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |